Design TherapeuticsvsJohnson & Johnson

DSGN and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

DSGN

Design Therapeutics, Inc.

$9.02

Value $556M

-3.22%
DSGN's page

Design Therapeutics (DSGN) has a market value of $556M and Johnson & Johnson (JNJ) $652B. Over the last year, with dividends, DSGN moved +22.9% and JNJ +36.6%. Dividend yield: DSGN none, JNJ 1.95%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    DSGN$556M

    JNJ$652B

    JNJ is 1,172 times DSGN

  • Revenue, 12 months

    DSGN$0

    JNJ$99.3B

  • Net income, 12 months

    DSGN-$74M

    JNJ$16.1B

  • Operating margin

    DSGN–

    JNJ–

  • ROIC

    DSGN-31.4%

    JNJ12.4%

    43.8 points apart

  • P/E

    DSGN–

    JNJ40.5

  • Dividend yield

    DSGN0.0%

    JNJ2.0%

    2.0 points apart

  • 5-year return

    DSGN-56.0%

    JNJ+90.9%

    146.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

DSGN-56.0%

JNJ+90.9%

010020020222023202420252026
Returns by period
PeriodDSGNWith dividendsJNJWith dividends
1 year since November 19, 2025+22.9%Price +22.9%+36.6%Price +33.6%
3 years since November 20, 2023+304.5%+59.3% a yearPrice +304.5%+94.9%+24.9% a yearPrice +80.4%
5 years since November 19, 2021-56.0%-15.2% a yearPrice -56.0%+90.9%+13.8% a yearPrice +66.0%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

DSGNDesign TherapeuticsJNJJohnson & Johnson

Valuation

DSGNJNJ
Valuation
Price$9.02$270.47
Market value$556M$652B
Enterprise value (EV)$348M$679B
P/E–40.5
P/E, 5-year median–21.9
P/B2.88.0
EV/EBIT–38.3
Free cash flow yield–3.2%

Results and growth

DSGNJNJ
Results and growth
Revenue, 12 months$0$99.3B
Net income, 12 months-$74M$16.1B
Free cash flow, 12 months-$59M$20.6B
Earnings per share, 12 months-$1.20$6.59
Revenue growth, year on year–6.1%
Revenue growth a year, past–+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

DSGNJNJ
Margins and returns on capital
Gross margin–67.6%
Operating margin––
Net margin–16.2%
ROIC-31.4%12.4%
ROE-35.8%19.7%

Balance sheet

DSGNJNJ
Balance sheet
Cash$209M$17.2B
Total debt$2.5M$44.7B
Net debt / EBITDA–1.1
Interest cover–18.0×

Dividends and buybacks

DSGNJNJ
Dividends and buybacks
Dividend yield–2.0%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: DSGN or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Design Therapeutics or Johnson & Johnson?

By market value, Johnson & Johnson ($652B) is about 1,171.7 times Design Therapeutics ($556M), at today's prices.

How did DSGN and JNJ stock do over the last 5 years?

Since November 19, 2021, DSGN's price moved -56.0% and JNJ's +66.0%. With dividends: DSGN -56.0% (-15.2% a year), JNJ +90.9% (+13.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, DSGN or JNJ?

The dividend yield at today's price is none for Design Therapeutics and 1.95% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which is the better investment, Design Therapeutics or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.